Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Suzanne R. Fanning"'
Autor:
Frederick Lansigan, D.J. Andorsky, Morton Coleman, Jeffrey P. Sharman, J. Li, Jr Ahn, Mecide Gharibo, Jason M. Melear, G.S. Nowakowski, Suzanne R. Fanning, Abdulraheem Yacoub, Mathias J. Rummel
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S73-(2021)
Objectives The combination of lenalidomide + rituximab (R2) has shown complementary clinical activity and is a tolerable regimen in both untreated and relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL), as well as mantle cell lymphoma (
Autor:
J. Li, Kathryn S. Kolibaba, Morton Coleman, Mecide Gharibo, Frederick Lansigan, Grzegorz S. Nowakowski, Jason M. Melear, Suzanne R. Fanning, Abdulraheem Yacoub, Jeffrey P. Sharman, C. Reynolds, Erin Ahn, D.J. Andorsky, Mathias J. Rummel
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S98-(2021)
Objectives Relapse is expected when treating patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL), with a shortened response associated with each relapse. Lenalidomide combined with rituximab (R2) has shown enhanced activity, with
Autor:
Juan C. Varela, Mohamad Cherry, Nikolaus S. Trede, Cesar O. Freytes, Don A. Stevens, Suzanne R. Fanning, Daanish Hoda, Bassam I. Mattar, James Lymp, Michael B. Maris, Habte A. Yimer, John E. Godwin, Carlos Bachier, James Essell, Marina Youssef, Jay Courtright
Publikováno v:
Blood. 136:50-52
Background: Currently approved CAR T cell therapies are generally administered as inpatient treatment at university medical centers due to concerns about the frequency, onset, severity, and management of AEs, including cytokine release syndrome (CRS)
Autor:
Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason M. Melear, Suzanne R. Fanning, Kathryn S. Kolibaba, Chris Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S172
Autor:
Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason M. Melear, Suzanne R. Fanning, Kathryn S. Kolibaba, Chris Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S384
Autor:
Mecide Gharibo, Jason M. Melear, D.J. Andorsky, Morton Coleman, Mathias J. Rummel, Frederick Lansigan, J. Li, G.S. Nowakowski, Jeffrey P. Sharman, Suzanne R. Fanning, Abdulraheem Yacoub, Jung Ryun Ahn
Publikováno v:
Hematological Oncology. 39
Autor:
Jay Courtright, Nikolaus S. Trede, Daanish Hoda, Habte A. Yimer, Paul Shaughnessy, J. Essell, Don A. Stevens, James Lymp, J. C. Varela, Suzanne R. Fanning, C.R. Bachier, Mohamad Cherry, Marina Youssef, Jeffrey P. Sharman, J. E. Godwin, Michael B. Maris, B. Mattar
Publikováno v:
Hematological Oncology. 39
Autor:
Morton Coleman, Kathryn S. Kolibaba, Jason M. Melear, C. Reynolds, Abdulraheem Yacoub, A.L. Et, G.S. Nowakowski, Frederick Lansigan, Suzanne R. Fanning, D.J. Andorsky
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss, Pp 222-(2020)
Autor:
Joseph Pidala, Betty K. Hamilton, Mohamed A. Kharfan-Dabaja, Eric J. Chow, Everett Meyer, Laura Johnston, Nina Shah, Shahrukh K. Hashmi, David I. Marks, Jeanne Palmer, Paul A. Carpenter, Yoshihiro Inamoto, Arnon Nagler, J. Douglas Rizzo, Linda J. Burns, Craig S. Sauter, Mehdi Hamadani, Stephanie J. Lee, Zachariah DeFilipp, Suzanne R. Fanning, Paul J. Shaughnessy, Cesar Rodriguez, Peter T. Curtin, Krishna V. Komanduri, Bipin N. Savani, Mohamad Mohty, Katherine Tarlock, J. Schriber, John R. Wingard, Navneet S. Majhail, Miguel-Angel Perales
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:1119-1124
Significant advances in hematopoietic cell transplantation (HCT) have increased the long-term survivorship of its recipients, but because of unique complications arising from radiation and chemotherapy, recipients require lifelong follow-up. To evalu
Autor:
David Andorsky, C. Reynolds, Abdulraheem Yacoub, Mathias J. Rummel, Mecide Gharibo, Jeff P. Sharman, Morton Coleman, Jason M. Melear, Grzegorz S. Nowakowski, Kathryn S. Kolibaba, Frederick Lansigan, Suzanne R. Fanning, J. Li, Jung Ryun Ahn
Publikováno v:
Blood. 138:812-812
Background: Patients with relapsed indolent NHL (iNHL) have limited standard treatment options. Lenalidomide combined with rituximab (R 2) has shown complimentary clinical activity and is a tolerable regimen in both untreated and relapsed or refracto